Answers are grounded in this paper and cite their sources.
Background: Lung-RADS category 3 and 4 nodules account for most cancers among screening-detected lung cancers and are considered actionable nodules with management implications. The cancer frequency among such nodules is estimated in the Lung-RADS recommendations and has been investigated primarily using retrospectively assigned Lung-RADS classifications. Objective: To assess the frequency of cancer among lung nodules assigned Lung-RADS category 3 or 4 at lung cancer screening (LCS) in clinical practice and factors that impact the cancer frequency within each category. Methods: This retrospective study was based on review of clinical radiology reports of 9148 consecutive low-dose CT LCS examinations performed in 4798 patients between June 2014 and January 2021 as part of an established LCS program. Unique nodules assigned Lung-RADS category 3 or 4 (4A, 4B, or 4X) that were clinically categorized as benign or malignant by a multidisciplinary conference, considering histologic analysis and follow-up imaging, were selected for further analysis; benign diagnoses based on stability required at least 12 months of follow-up imaging. Indeterminate nodules were excluded. Cancer frequencies were evaluated. Results: Of the 9148 LCS examinations, 857 (9.4%) were assigned Lung-RADS category 3, and 721 (7.9%) were assigned category 4. The final analysis included 1297 unique nodules in 1139 patients (598 men, 541 women; mean age, 66.0±6.3 years). A total of 1108/1297 (85.4%) nodules were deemed benign, and 189/1297 (14.6%) were deemed malignant. Frequencies of malignancy for category 3, 4A, 4B, and 4X nodules were 3.9%, 15.5%, 36.3%, and 76.8%, respectively. A total of 45/46 (97.8%) endobronchial nodules (all category 4A) were deemed benign based on resolution. Cancer frequency was 13.1%, 24.4%, and 13.5% for solid, part-solid, and ground-glass nodules, respectively. Conclusions: When applying Lung-RADS for LCS clinical practice, the frequency of Lung-RADS category 3 and 4 nodules, as well as cancer frequency in these categories, were higher than prevalence and cancer risk estimated for category 3 and 4 nodules in the Lung-RADS recommendations and reported in earlier studies using retrospective category assignments. Nearly all endobronchial category 4A nodules were benign. Clinical Impact: Future Lung-RADS iterations should consider these findings from real-world practice to improve the system's clinical utility.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: